Biogen Idec Investigates Tysabri in Secondary-Progressive Multiple Sclerosis Patients

Click here to receive MS news via e-mail
Biogen Idec

Biogen Idec is currently sponsoring a clinical trial evaluating its therapy Tysabri (natalizumab) in patients with secondary-progressive multiple sclerosis. Although relapse-remitting multiple sclerosis is more common and well-researched, the National Multiple Sclerosis Society estimates approximately half of relapse-remitting patients will transition to secondary-progressive within 19 years of diagnosis.

Biogen IdecThe Phase 3b clinical trial is a multicenter, international study known as “A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis,” or simply “ASCEND in SPMS.” It is a two-part study, with part one placebo-controlled and part two open-label.

The primary objective of the placebo-controlled study is to evaluate slowed disability progression in patients treated with natalizumab. Patients will be evaluated with the Expanded Disability Status Scale, Timed 25-Foot Walk, and/or 9-Hole Peg Test. Secondary objectives will focus on clinical outcomes such as brain volume using MRI scans.

During the open-label extension study, patients will be monitored for adverse and serious adverse effects to solidify the safety profile of natalizumab. Secondary measures will continue to evaluate disability progression.

An estimated 856 patients are participating in the trial, and natalizumab will be administered once a month intravenously. Patients will receive treatment for a total of 96 weeks, and the study duration is 108 weeks. The trial is predicted to end in December 2014.

[adrotate group=”4″]

The difference between relapse-remitting and secondary-progressive multiple sclerosis is the presence or absence of periods of relapse, respectively. Whereas relapse-remitting patients go through periods of partial recovery, secondary-progressive patients see a continual worsening of symptoms due to steady nerve damage. Consequently, they generally have greater losses of independence and quality of life.

“There are limited treatment options available to people living with secondary-progressive multiple sclerosis, and there is a high unmet need for effective therapies,” stated Aaron Miller, MD, a member of the ASCEND advisory board, in a press release from Biogen Idec at the beginning of the study. “The ASCEND trial is investigating whether treatment with Tysabri may prevent worsening in walking, hand movement and daily functioning in these patients.”

Tagged , , , .

Maureen Newman is a science columnist for BioNews Texas. She is currently a PhD student studying biomedical engineering at University of Rochester, working towards a career of research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit's laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment.
Click here to receive MS news via e-mail


  1. David Lennon says:

    Thanks for the information, Maureen. Since I first read this I’ve been awaiting news of the outcome of the trial which you mention above as being predicted to end in December 2014. I’ve seen nothing in the media. Are you aware of any further developments? my wife has SPMS, and reacted badly to simvastatins, so Tysabri is really our only other option.
    Many thanks, David

  2. Maureen NewmanMaureen Newman says:

    Hello David. Checking on the clinical trial, the primary study completion date has been pushed back to October 2015, with the final study completion expected in March 2017. I was not been able to find any publications indicating preliminary results, but I will keep an eye out. If you want to track the study as well, this is the url to the clinical trial:

    Best wishes to you and your wife. -Maureen

  3. Sam Smith says:

    Hi Maureen, is the primary completetion date for the spms trial still October, How long from Primary completion date to results being published any idea.

    Kind regards


Leave a Comment

Your email address will not be published. Required fields are marked *